Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib in BRCA-mutated Ovarian Cancer and Solid Tumors
NCT01482715Phase 2Completed
- Sponsor
- pharma&
- Start
- Nov 2011
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of rucaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (4 arms), sponsored by pharma&. Primary endpoints: Overall Response Rate at 8 months, Dose Limiting Toxicity at 21 days and 3 more. Started Nov 2011; status: completed.
02
Drugs
rucaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)solid tumor
Beyond the preview
Go deeper on NCT01482715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01482715.